Eczema (Oatmeal)
Brand Names: Eczema
Methodology & AI Transparency ⓘ
Eczema (Oatmeal) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary non-standardized food allergenic extract presentation registered by ORGANIC & SUSTAINABLE BEAUTY, Eczema supplies active moiety Oatmeal (cross-referenced at /meds/oatmeal) in 10 mg/mL Cream; 10 mg/mL Lotion/Shampoo (NDC 52915-010, 52915-120; SPL 2024-11-05).
- 2 Real-world patient consensus: Registered under RxNorm 1437616-B52915010 and SPL 2024-11-05, pairing Eczema packaging with active ingredient Oatmeal.
- 3 Typical cash cost range: Public pharmacy ledger: $31.54 low cash benchmark vs. $83.58 chain retail average ($0.3200/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Eczema (Oatmeal) tolerability events: pruritus (4.2%), application-site irritation (6.7%), nausea (7.6%).
Ask our AI Specialists anything about Eczema (Oatmeal)
Eczema (Oatmeal) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary non-standardized food allergenic extract presentation registered by ORGANIC & SUSTAINABLE BEAUTY, Eczema supplies active moiety Oatmeal (cross-referenced at /meds/oatmeal) in 10 mg/mL Cream; 10 mg/mL Lotion/Shampoo (NDC 52915-010, 52915-120; SPL 2024-11-05). Clinical prescribing and dispensing guidelines focus on Uses Temporarily protects and helps relieve minor skin irritation and itching due to: Rashes Eczema Poison ivy, oak, or.
The active constituent inside Eczema—Oatmeal—functions as a targeted non-standardized food allergenic extract agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Oatmeal, Eczema (registered by ORGANIC & SUSTAINABLE BEAUTY, SPL 2024-11-05) specifies proprietary packaging (52915-010, 52915-120) and 10 mg/mL Cream; 10 mg/mL Lotion/Shampoo quality controls alongside a $0.3200/unit NADAC acquisition baseline.
Following administration (10 mg/mL Cream), Eczema (Oatmeal) achieves < 5% transdermal or mucosal systemic uptake from Eczema (Oatmeal) bioavailability and initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (eczema (oatmeal)) onset, governed by a Localized tissue retention for Eczema (Oatmeal) with minimal systemic plasma half-life terminal half-life through local esterase/enzymatic cleavage of eczema (oatmeal) with minimal hepatic cytochrome burden.
Before initiating Eczema (Oatmeal) at 10 mg/mL Cream, clinical safety checklists rule out documented intolerance or hypersensitivity reaction involving oatmeal (non-standardized food allergenic extract); concurrent restricted medications flagged in section 4/7 of the eczema (oatmeal) dailymed monograph (1437616-b52915010). Logged tolerability patterns center on headache (7.7% of reports), nausea (7.6% of reports), application-site irritation (6.7% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Eczema (Oatmeal) (non-standardized food allergenic extract).
Botanical enzyme modulators may alter oral first-pass exposure of Eczema (Oatmeal); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Oatmeal (non-standardized food allergenic extract)
- Concurrent restricted medications flagged in Section 4/7 of the Eczema (Oatmeal) DailyMed monograph (1437616-B52915010)
Logged Side-Effect Incidence (6 Reports)
Eczema (Oatmeal) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Eczema (Oatmeal))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With: What a 639-Participant Study Found Delgocitinib cream resulted in clinically significant improvement in HRQoL compared with cream vehicle. Contact dermatitis • 2026-07-15 • Phase III Randomized Trial | N = 639 | 93/100 | PMID 41775339 ↗ |
| New Insights on Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients: What a 564-Participant Study Found LEB was associated with high rates of durable absolute EASI response, even in cases of high baseline severity or suboptimal week-16 outcomes. Acta dermato-venereologica • 2026-05-21 • Phase III Randomized Trial | N = 564 | 93/100 | PMID 42163822 ↗ |
| What the Latest Evidence Really Says About Factors associated with depression, anxiety and severe mental illness among Our review highlights limited existing research on factors associated with depression, anxiety and SMI in adults with AE or psoriasis. The British journal of dermatology • 2023-03-30 • Meta-Analysis | Multi-cohort | 92/100 | PMID 36745557 ↗ |
| Can This Approach Help? Inside the Latest Research on Difamilast ointment in adult patients with eczema: A phase 3 randomized, Difamilast ointment 1% demonstrated superiority to the vehicle and favorable safety in adult Japanese patients with eczema. Journal of the American Academy of Dermatology • 2022-03-15 • Phase III Randomized Trial | N = 182 | 88/100 | PMID 34710557 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe Upadacitinib 15 mg and 30 mg single-drug treatment provided rapid and sustained improvement in atopic hand eczema compared with placebo through Week 16 in patients with moderate-to-severe AD. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37184290 ↗ |
Eczema (Oatmeal) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.3200/unit (~$9.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $83.58 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $31.54 / mo | View logs ↓ |
Eczema (Oatmeal) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Eczema (Oatmeal) RxNorm Concept ID | 1437616-B52915010 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $83.58 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $31.54 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Eczema (Oatmeal) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Eczema (Oatmeal) integrating DailyMed SPL (2024-11-05), CMS NADAC ($0.3200/unit), and 6 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Eczema (Oatmeal) community threads and patient logs by age, biological sex, dosage, and treatment duration.